Hansky 1969.

Methods	Randomised clinical trial
Participants	Country: Australia Number randomised: 24 Postrandomisation dropouts: not stated Revised sample size: 24 Average age: not stated Women: 7 (29.2%) Acute interstitial oedematous pancreatitis: not stated Necrotising pancreatitis: not stated Mild pancreatitis: 3 (12.5%) Moderate pancreatitis: 15 (62.5%) Severe pancreatitis: 6 (25%) Persistent organ failure: not stated Infected pancreatitis: not stated Inclusion criteria: people with acute pancreatitis
Interventions	Group 1: iniprol (n = 15), single IV dose of 1 million units, followed by 500,000 units IV 4 times daily for 4‐8 days depending upon clinical course Group 2: no intervention (n = 9)
Outcomes	Mortality, hospital stay Follow‐up: not stated (probably until discharge)
Notes	Reasons for postrandomisation dropouts: not stated
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Comment: this information was not available.
Allocation concealment (selection bias)	Unclear risk	Comment: this information was not available.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Quote: "[t]he drug was not evaluated in a double‐blind manner".
Blinding of outcome assessment (detection bias) All outcomes	High risk	Quote: "[t]he drug was not evaluated in a double‐blind manner".
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: this information was not available.
Selective reporting (reporting bias)	High risk	Comment: either mortality or adverse events were not reported.
For profit‐bias	High risk	Quote: "I am grateful to Difrex (Australia) laboratories for supplying . . ."
Other bias	Low risk	Comment: no other risk of bias